Phosphodiesterase 9 Inhibition Combined With Valsartan and With Sacubitril/Valsartan in Experimental Ovine Heart Failure
LCZ696 and PDE9i+valsartan have similar beneficial hemodynamic and renal effects in HF, with combined PDE9i+LCZ696 producing additional improvements. Overall, effects were significantly greater in severe HF. Findings suggest PDE9i might serve as a replacement for neprilysin inhibition or as an adjunct therapy to LCZ696.
Authors
- Miriam T. Rademaker (ORCID: https://orcid.org/0000-0002-3470-5979)
- Timothy C. R. Prickett (ORCID: https://orcid.org/0000-0002-9684-5096)
- Mark Richards (ORCID: https://orcid.org/0000-0002-2023-8177)
- Christopher J. Charles (ORCID: https://orcid.org/0000-0001-9807-8022)
- Nicola Scott (ORCID: https://orcid.org/0000-0002-5685-9151)
- Christopher Frampton
Institutions
- University of Otago (NZ)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1161/jaha.124.036689
- Citations
- 2
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Pfizer
- University of Otago
- National Heart Foundation of New Zealand
- Canterbury Medical Research Foundation